Anti-VEGF therapy

Anti-VEGF therapy

While anti-vascular endothelial growth factor (anti-VEGF)

therapy is a common and effective treatment for wet agerelated macular degeneration (AMD),

 it is also beneficial in treating eyes with macular neovascularization (MNV) complicating pachychoroid disease.

 Dr. Enrico Borrelli from the University Vita-Salute San Raffaele, Italy, shared that in the MINERVA study,

eyes with MNV secondary to CSC were treated with ranibizumab and experienced a gain of 6.6 letter in visual acuity at a two-month follow-up visit,

 in contrast with a gain of 1.6 let-ter in the sham group.

He noted that as most patients with pachychoroid disease complicated by MNVs are older than 50 years, ลาวสามัคคี วีไอพี

it would be challenging to differentiate pachychoroid disease complicated by exudative MNV from AMD, as these two conditions may have similar characteristics on dye angiographies.

 He investigated the relative prevalence of neovascular AMD and exudative MNV secondary to pachychoroid disease

 in patients older than 50 years with evidence of treatment-naïve exudative MNV over a period of two years,

and found that visual prognosis is overall better in MNV complicating pachychoroid disease.

 “Subjects with pachychoroid disease complicated by MNV have a significantly longer treatment-free interval than subjects with neovascular AMD after a loading dose of anti-VEGF therapy.

The latter finding was speculated to be related to lower secretion of VEGF in pachychoroid disease,” shared Dr. Borrelli.

He added that pachychoroid disease is a frequent cause of exudative MNV in aged patients with a high rate of misdiagnosis.

 It is, therefore, important to perform a correct diagnosis as these two disorders differ in terms of clinical characteristics and prognosis.

Anti-VEGF therapy is effective in these cases and PDT may be considered as a combined therapy.

In a following presentation, Dr. Dinah Zur from the Tel Aviv University, Israel, commented that anti-VEGF treatment is effective

and requires less frequent injections in pachychoroid aneurysmal type 1 MNV than in nAMD as well,

with a mean of 3.5-4.6 annual injections (ranibizumab, aflibercept)

For more information:  ลาวสามัคคี วีไอพี


อีเมลของคุณจะไม่แสดงให้คนอื่นเห็น ช่องข้อมูลจำเป็นถูกทำเครื่องหมาย *